Faehling M, Schumann C, Christopoulos P, et al. - Given that durvalumab has received approval for consolidation of locally advanced PD-L1(programmed-death ligand 1)-positive non-small cell lung cancer post-chemoradiotherapy after the PACIFIC trial, the effectiveness and safety of durvalumab was tested in patients in the EAP (expanded access program) from November 22, 2017 to October 15, 2018. Researchers focused on adverse events, progression-free survival, overall survival by analyzing data from 56 centers. At least 1 cycle durvalumab was received by 126 patients. The participants in the EAP had more advanced stage and included “oligometastatic” stage IV patients and patients with autoimmune disease vs those in the PACIFIC trial. PFS and OS were comparable in the EAP and the PACIFIC trial. Durvalumab consolidation may be beneficial for certain stage IV patients and patients experiencing autoimmune disease. Survival was not predicted by PD-L1, so PD-L1-negative patients should not be excluded from durvalumab consolidation. Overall, findings demonstrated the effectiveness as well as the safety of durvalumab consolidation in a European real-world setting.